The effect of levosimendan on blood coagulation after cardiac surgery.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2009-013957-13-FI

Enrollment

Registered

2009-07-15

Start date

2009-09-21

Completion date

Unknown

Last updated

2024-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepelvaltimotauti I20.0 Sydämen vajaatoiminta I50.0

Interventions

Trade Name: Simdax 2.5 mg/mL Product Name: Simdax 2.5 mg/mL Product Code: no Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: LEVOSIMENDAN CAS Number: 141505-33-1 Pharma

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Vaseman kammion ejektio fraktio 30-50% CABG leikkaus Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Munuaisten, maksan vajaatoiminta Verenvuotosairaus Antitromboottinen lääkitys mikäli ei ole keskitetty 7 päivää ennen leikkausta

Design outcomes

Primary

Measure	Time frame
Main Objective: Tutkimuksen tavoitteena on selvittää levosimendaanin vaikutusta veren hyytymiseen sydänleikkauksen jälkeen randomoidussa placebo-kontrolloidussa asetelmassa.;Secondary Objective: ;Primary end point(s): Tromboelastometria parametrit Verihiutaleiden funktio (Multiplate) Teho-hoitoaika	—

Countries

Finland

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026